QR Kodea

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research

BackgroundRearranged during transfection (RET) fusion is a kind of uncommon mutation (about 1%) in non-small cell lung cancer (NSCLC). Although selective tyrosine kinase inhibitors (TKI) (selpercatinib and pralsetinib) have been available, there are no real-world data about the difference in the eff...

Deskribapen osoa

Gorde:
Egile Nagusiak: Yan Meng, Yilin Yang, Yujia Fang, Xinqing Lin, Xiaohong Xie, Haiyi Deng, Jianhui Wu, Maolin Zhou, Ni Sun, Zhanhong Xie, Ming Liu, Ming Ouyang, Yinyin Qin, Chunxia Su, Chengzhi Zhou
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2022-05-01
Saila:Frontiers in Oncology
Gaiak:
RET
NSCLC
tyrosine kinase inhibitors
survival
risk factor
Sarrera elektronikoa:https://www.frontiersin.org/articles/10.3389/fonc.2022.864367/full
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak